CJC – 1295 Doses

Mod GRF 1-29, as well as the majority of other growth hormone releasing peptides, are very new substances on the market, and there exists at this point in time (as of 2013) a limited amount of clinical data and general information in regards to Mod GRF 1-29 doses. Solid protocols have indeed been developed, but what should be noted is that Mod GRF 1-29 (CJC-1295 without DAC) is yet to be approved or utilized in medicine, and clinical trials of Mod GRF 1-29, as well as many other peptide hormones, are still in the midst of research. With that having been said, the limitation of clinical data and general information on CJC-1295 without DAC doses have not prevented athletes, bodybuilders, and those within the performance enhancing drug using community from taking advantage of its effects through use. Therefore, there is enough data currently to provide information on proper and effective Mod GRF 1-29 doses.

Natural endogenously produced GHRH is secreted by the hypothalamus, and travels directly to the anterior pituitary gland in order to bind to receptors there and stimulate HGH release. GHRH and its analogues (like Mod GRF 1-29) have a tendency to already possess very short half-lives due to the high affinity for the bonds between the amino acids in the peptides to be cleaved by enzymes in the body. Because naturally secreted GHRH does not travel very far between the hypothalamus and the pituitary gland, very little of it is broken down by enzymes during travel. However, Mod GRF 1-29 and related GHRH analogues must travel a long ways to the pituitary gland through circulation after injection, and within approximately 3 minutes, breakdown of the peptide already occurs. Therefore, Mod GRF 1-29 doses must be high in comparison to endogenously produced GHRH in order to achieve saturation of the receptors on the anterior pituitary.

Saturation doses are defined as doses that fully saturate the target receptors in the body (in this case, the receptors located on the anterior pituitary). This means that a 100mcg saturation dose will fully saturate receptors, and that 200mcg will only provide 50% additional effectiveness, and a 300mcg dose will provide only 25% additional effectiveness, and so on and so forth.

Mod GRF 1-29 doses are measured in mcg (micrograms), and readers should take note of this due to the common measurement of other performance enhancing drugs (such as anabolic steroids) in mg (milligrams). Synthetic Human Growth Hormone (HGH) is measured in iu (international units). The difference in distinguishing between the different dosing measurements must be taken into account.

Medical Modified GRF 1-29 (CJC-1295 without DAC) Doses

Because Mod GRF 1-29 (CJC-1295 without DAC) is not currently yet approved for medical use and is still in the phase of clinical trials, there are no prescription medical doses currently available.

Mod Modified GRF 1-29 (CJC-1295 without DAC) Doses for Performance and Physique Enhancement

For the purpose of performance and physique enhancement, peptides such as Mod GRF 1-29 in particular cannot be categorized into the three tiers of users (beginner, intermediate, and advanced) due to the inherent nature of the type of substance and hormone. As a result, there is a general single across-the-board protocol of Mod GRF 1-29 doses that have been determined and established, as the increases of HGH from the pituitary are generally large enough to benefit any person.

Research has demonstrated that an effective saturation dose of Mod GRF 1-29 is 100mcg/kg of bodyweight[1] [2] [3] [4]. 100mcg of Mod GRF 1-29 would require an individual who is 100kg of bodyweight, which is 220 lbs. Therefore, for ease of administration and confusion, the standard general Mod GRF 1-29 dose is that of 100mcg for nearly all users in order to achieve saturation of the receptors on the anterior pituitary gland at any given time. 100mcg should be administered three times per day spaced evenly apart in order to achieve substantial HGH levels throughout the day due to its short 30 minute half-life, and the pulsatile manner of the HGH release that it causes (this will be further explained shortly).

Female Modified GRF 1-29 (CJC-1295 without DAC) Doses

Mod GRF 1-29 is not a sex-specific hormone and therefore carries no androgenic effects that would present any issues. Therefore, female Mod GRF 1-29 doses are the exact same as that of males and everyone else.

Questions PeptidesProper Administration and Timing of Modified GRF 1-29 (CJC-1295 without DAC) Doses

Mod GRF 1-29 is typically manufactured as lyophilized (freeze-dried) powder in amounts of 2mg per vial. This powder within the vial must be reconstituted with bacteriostatic water before injection, and promptly refrigerated after constitution and after each use due to its peptide nature. If left unrefrigerated at room temperature for extended periods of time, the reconstituted peptide will quickly degrade and become ineffective. When reconstituting, typically 2ml of bacteriostatic water is gently mixed into the powder (normally an amount of 2mg of powder) which will then yield a Mod GRF 1-29 dose of 100mcg per 0.1ml (or 10iu on an insulin syringe).

Mod GRF 1-29 (CJC-1295 without DAC) can be administered subcutaneously (SQ) or intramuscularly (IM). There is not much difference between the two, with intramuscular seemingly resulting in a slightly quicker release from the injection site. The majority of individuals prefer to administer it subcutaneously for varying reasons, however.

There are a few important points to consider and understand concerning Mod GRF 1-29 doses (or doses of any type of GHRH). The first point is that administration of any GHRH should be done no sooner than 30 minutes prior to any meal containing fats and carbohydrates, and at least 2 hours following any meal containing fats and carbohydrates. This is because fats and carbohydrates both exhibit a blunting effect on the release of HGH from the pituitary gland, and therefore consuming these two macronutrients too soon before or after administration will hamper the full pulse of HGH release from the pituitary. Once HGH levels have reached their peak from the pulse, which is 30 minutes following administration, it will then be safe to consume a meal containing carbohydrates and fats.

Because GHRH analogues such as Mod GRF 1-29 (CJC-1295 without DAC) stimulate HGH release in a pulsatile manner, multiple Mod GRF 1-29 doses are required throughout the day that are typically administered on average 3 times daily spaced evenly apart. The most common protocol is as follows:

100mcg immediately upon waking up
100mcg immediately following the end of a workout
100mcg immediately before bed

The three times per day application of 100mcg of GRF 1-29 doses is said to provide HGH release that is desired for bodybuilding and performance enhancement. Some opt for twice daily application (100mcg in the morning and before bed), which is said to provide HGH release that is desired for anti-aging and general health benefits. Some will opt to also administer Mod GRF 1-29 (CJC-1295 without DAC) even more than three times per day, which would obviously generate much higher levels of HGH. However, it is important to ensure at least 3 hours between each administration of any GHRH so as to ensure adequate HGH levels are once again restored within the pituitary for optimal release.

It has been previously mentioned that GHRH analogues such as Mod GRF 1-29 should typically be utilized with a GHRP (also known as a Ghrelin mimetic) such as GHRP-6 or Ipamorelin. This is because GHRH and GHRP peptides are synergistic in the manner by which they stimulate the anterior pituitary to release HGH. GHRH alone is only effective when Somatostatin (a hormone that inhibits HGH release from the pituitary) is low. Any GHRP will serve to inhibit Somatostatin and this will serve as one of the multiple methods that GHRPs will potentiate Mod GRF 1-29’s (or any GHRH’s) effects. In general summary of the synergistic effect of both: a GHRH analogue (such as Mod GRF 1-29) will serve to initiate and carry forward the pulse of HGH from the pituitary gland, while the GHRP (such as GHRP-6) will serve to amplify this pulse.

Lastly, a single administration of 100mcg of any GHRH by itself resulted in 25ng/ml of HGH released from the pituitary according to studies[5]. The same study determined that when combined with a GHRP (GHRP-6), the resultant HGH release was determined to be 130 ng/ml.

Expectations and Results from Modified GRF 1-29 (CJC-1295 without DAC) Doses

Results and expectations from an HGH secretagogue such as Mod GRF 1-29 should be all of the same effects that any other form of Human Growth Hormone would provide. This includes fat loss, muscle mass increases, strength gains, healing and repair of joints and connective tissue, and a plethora of other benefits and changes. An important note to make is that the effects from any HGH application, whether it be an endogenous release from a GHRH or synthetic HGH administration, will all occur rather steadily over a longer period of use. Dramatic results within weeks are never to be expected, but with proper nutrition and training, dramatic performance and physique changes should occur steadily over the course of several months of application. For more information on HGH specific results and expectations, please see the Human Growth Hormone profile.


CJC-1295 References:

[1] EFFECTS OF A GRCWTH HORMONE RELEASING FACTOR IN MAN. Marie C. Gelato, Ora Pescovitz, Fernando Cassorla, D. lynn Fernando and George R. Merriam. The Journal of Clinical Endocrinology & Metabolism September 1, 1983 vol. 57 no. 3 674-676.

[2] α2-Adrenergic Agonism Enhances the Growth Hormone (GH) Response to GH-Releasing Hormone through an Inhibition of Hypothalamic Somatostatin Release in Normal Men*. JESUS DEVESA, VICTOR ARCE†, NOEMI LOIS, JESUS A. F. TRESGUERRES and LUIS LIMA. The Journal of Clinical Endocrinology & Metabolism December 1, 1990 vol. 71 no. 6 1581-1588

[3] Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons. L Lima, V Arce, M J Diaz, J A Tresguerres and J Devesa. The Journal of Clinical Endocrinology & Metabolism February 1, 1993 vol. 76 no. 2 439-444.

[4] Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Lucie Jetté, Roger Léger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, Véronique Paradis, Pieter van Wyk, Khan Pham and Dominique P. Bridon. Endocrinology July 1, 2005 vol. 146 no. 7 3052-3058.

[5] Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing’s syndrome. Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF. Clin Endocrinol (Oxf). 1994 Nov;41(5):649-54.